WO1999063973A3 - PHARMACEUTICAL COMPOSITIONS AND USES FOR ANDROST-5-ENE-3β,17β-DIOL - Google Patents

PHARMACEUTICAL COMPOSITIONS AND USES FOR ANDROST-5-ENE-3β,17β-DIOL Download PDF

Info

Publication number
WO1999063973A3
WO1999063973A3 PCT/CA1999/000537 CA9900537W WO9963973A3 WO 1999063973 A3 WO1999063973 A3 WO 1999063973A3 CA 9900537 W CA9900537 W CA 9900537W WO 9963973 A3 WO9963973 A3 WO 9963973A3
Authority
WO
WIPO (PCT)
Prior art keywords
loss
androst
ene
diol
pharmaceutical compositions
Prior art date
Application number
PCT/CA1999/000537
Other languages
French (fr)
Other versions
WO1999063973A2 (en
Inventor
Fernand Labrie
Original Assignee
Endorech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to HU0102483A priority Critical patent/HUP0102483A3/en
Priority to EP99924625A priority patent/EP1083904A2/en
Priority to BR9911115-2A priority patent/BR9911115A/en
Priority to JP2000553042A priority patent/JP2002517432A/en
Priority to IL14022599A priority patent/IL140225A0/en
Priority to PL99345955A priority patent/PL345955A1/en
Priority to AU41274/99A priority patent/AU4127499A/en
Priority to CA002334702A priority patent/CA2334702C/en
Application filed by Endorech Inc filed Critical Endorech Inc
Priority to MXPA00012304A priority patent/MXPA00012304A/en
Publication of WO1999063973A2 publication Critical patent/WO1999063973A2/en
Publication of WO1999063973A3 publication Critical patent/WO1999063973A3/en
Priority to NO20006286A priority patent/NO20006286L/en
Priority to HK01108194A priority patent/HK1037329A1/en
Priority to IL175723A priority patent/IL175723A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Androst-5-ene-3β,17β diol is used to treat or reduce the likelihood of acquiring osteoporosis or menopausal symptoms, or other diseases affected by estrogen receptor activity, like vaginal atrophy, hyporgonadism, diminished libido, skin atrophy, urinary incontinence, ovarian cancer, uterine cancer, endometriosis, obesity, cardiovascular disease, loss of muscle mass, loss of energy or fatigue, Alzheimer's disease and loss of memory and for conditions which respond well to DHEA treatment, but where a higher ratio of estrogenic to androgenic effects is desired. Combination therapies are included, as are kits and pharmaceutical compositions for providing the active ingredients of claimed methods and combinations.
PCT/CA1999/000537 1998-06-11 1999-06-10 PHARMACEUTICAL COMPOSITIONS AND USES FOR ANDROST-5-ENE-3β,17β-DIOL WO1999063973A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
AU41274/99A AU4127499A (en) 1998-06-11 1999-06-10 Pharmaceutical compositions and uses for androst-5-ene-3beta,17beta-diol
BR9911115-2A BR9911115A (en) 1998-06-11 1999-06-10 Pharmaceutical compositions and uses for oandrost-5-ene-3 beta, 17 beta-diol
JP2000553042A JP2002517432A (en) 1998-06-11 1999-06-10 Pharmaceutical composition and use of androst-5-ene-3β, 17β-diol
IL14022599A IL140225A0 (en) 1998-06-11 1999-06-10 PHARMACEUTICAL COMPOSITIONS AND KITS CONTAINING ANDROST-5-EN-3beta; 17beta;-DIOL OR PRODRUGS THEREOF
PL99345955A PL345955A1 (en) 1998-06-11 1999-06-10 PHARMACEUTICAL COMPOSITIONS AND USES FOR ANDROST-5-ENE-3β,17β-DIOL
HU0102483A HUP0102483A3 (en) 1998-06-11 1999-06-10 Pharmaceutical compositions containing androst-5-ene-3betha,17betha-diol
CA002334702A CA2334702C (en) 1998-06-11 1999-06-10 Pharmaceutical compositions and uses for androst-5-ene-3.beta.,17.beta.-diol
EP99924625A EP1083904A2 (en) 1998-06-11 1999-06-10 Pharmaceutical compositions and uses for androst-5-ene-3 beta,17 beta-diol
MXPA00012304A MXPA00012304A (en) 1998-06-11 1999-06-10 PHARMACEUTICAL COMPOSITIONS AND USES FOR ANDROST-5-ENE-3beta,17beta-DIOL.
NO20006286A NO20006286L (en) 1998-06-11 2000-12-11 Pharmaceutical compositions and applications for androst-5-one-3 <beta> -, 17 <beta> -diol
HK01108194A HK1037329A1 (en) 1998-06-11 2001-11-21 Pharmaceutical compositions and uses for androst-5-ene-3beta, 17beta-diol
IL175723A IL175723A0 (en) 1998-06-11 2006-05-17 Pharmaceutical compositions and kits containing androst-5-ene-3??, 17??-diol or prodrugs thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9628698A 1998-06-11 1998-06-11
US09/096,286 1998-06-11

Publications (2)

Publication Number Publication Date
WO1999063973A2 WO1999063973A2 (en) 1999-12-16
WO1999063973A3 true WO1999063973A3 (en) 2000-11-02

Family

ID=22256669

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1999/000537 WO1999063973A2 (en) 1998-06-11 1999-06-10 PHARMACEUTICAL COMPOSITIONS AND USES FOR ANDROST-5-ENE-3β,17β-DIOL

Country Status (23)

Country Link
US (12) US6432940B1 (en)
EP (2) EP1083904A2 (en)
JP (1) JP2002517432A (en)
KR (3) KR20060098400A (en)
CN (3) CN100377711C (en)
AR (1) AR018660A1 (en)
AU (1) AU4127499A (en)
BR (1) BR9911115A (en)
CA (1) CA2334702C (en)
HK (2) HK1037329A1 (en)
HU (1) HUP0102483A3 (en)
ID (1) ID27922A (en)
IL (2) IL140225A0 (en)
MX (1) MXPA00012304A (en)
MY (1) MY131522A (en)
NO (1) NO20006286L (en)
NZ (1) NZ536787A (en)
PL (1) PL345955A1 (en)
RU (1) RU2221569C2 (en)
TR (2) TR200102867T2 (en)
TW (2) TWI283579B (en)
WO (1) WO1999063973A2 (en)
ZA (1) ZA200007299B (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1083904A2 (en) * 1998-06-11 2001-03-21 Endorecherche Inc. Pharmaceutical compositions and uses for androst-5-ene-3 beta,17 beta-diol
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6667299B1 (en) * 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
US20060079492A1 (en) * 1999-10-25 2006-04-13 Ahlem Clarence N Compositions and treatment methods
PL352250A1 (en) 1999-06-11 2003-08-11 Watson Pharmaceuticals Administration of non-oral androgenic steroids to women
CA2376158C (en) 1999-07-06 2011-03-15 Endorecherche, Inc. Use of selective estrogen receptor modulators in the manufacture of medicaments for treating and/or suppressing weight gain
CA2669753C (en) 1999-09-30 2012-06-26 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment of androgen receptor driven conditions
AU7896100A (en) * 1999-10-14 2001-04-23 Endorecherche Inc. Selective estrogen receptor modulators in the treatment or reduction of the riskof acquiring hypertension, cardiovascular diseases, and insulin resistance
FR2803750B1 (en) * 2000-01-17 2004-04-02 Assist Publ Hopitaux De Paris ORAL USE OF DEHYDROEPIANDROSTERONE, ITS BIOLOGICAL PRECURSORS AND ITS METABOLIC DERIVATIVES AS AN ANTI-ATROPHYANT
AU2001241779A1 (en) 2000-02-25 2001-09-03 Hollis-Eden Pharmaceuticals, Inc. Method of treatment of prostate cancer
DE10039199A1 (en) * 2000-08-10 2002-02-21 Schering Ag Combination preparations from an ERß selective estrogen and a SERM or antiestrogen
FR2825277B1 (en) * 2001-05-30 2004-10-15 Oreal COSMETIC AND / OR DERMATOLOGICAL AND / OR PHARMACEUTICAL COMPOSITION CONTAINING AT LEAST ONE ENZIME 3, B-HSD IHNIBITOR COMPOUND
DE10151363A1 (en) * 2001-10-17 2003-05-08 Schering Ag Use of estrogen receptor beta agonists to prepare medicaments for producing somatotropic and organotropic effects on the CNS, circulatory, skeletal and immune system in aging men and women
WO2003070253A1 (en) * 2002-02-21 2003-08-28 Pantarhei Bioscience B.V. Estrogenic component for treating decreased libido in women
WO2003090754A1 (en) * 2002-04-23 2003-11-06 Sahltech I Göteborg AB Use of dhea for treatment of female hypopituitarism
CA2496867A1 (en) * 2002-08-28 2004-03-11 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment methods
US20050101581A1 (en) * 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2
GB0302572D0 (en) 2003-02-05 2003-03-12 Astrazeneca Ab Method of treatment
AU2005265174A1 (en) * 2004-06-23 2006-01-26 Merck & Co., Inc. Estrogen receptor modulators
EA014878B1 (en) 2004-10-20 2011-02-28 Эндорешерш, Инк. Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cgmp phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women
BRPI0517950A (en) * 2004-11-01 2008-10-21 Endorech Inc use of androgens to reduce the likelihood of acquiring or to treat skin aging
EP1967202A1 (en) * 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
EP2185112A4 (en) * 2007-08-21 2012-01-18 Harbor Biosciences Inc Stabilized therapeutic compositions and formulations
EP2053055A1 (en) * 2007-10-24 2009-04-29 Bayer Schering Pharma Aktiengesellschaft 11.beta.-fluoro-3-acetoxyestra-3,5-diene-17-one and method for its manufacture
JP2010109894A (en) * 2008-10-31 2010-05-13 Fujitsu Ltd Acoustic wave filter, duplexer, communication module, and communication apparatus
US20100317635A1 (en) * 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
AU2014201406B2 (en) * 2009-06-16 2016-08-11 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
CA2802761C (en) 2010-06-16 2017-01-03 Endorecherche, Inc. Methods of treating or preventing estrogen-related diseases
US20130178747A1 (en) * 2012-01-10 2013-07-11 Peter J. Muran Breast cancer precursor evaluation system and proactive breast wellness program
CN105037532B (en) * 2015-07-27 2018-02-09 苏州博源医疗科技有限公司 17 ketosteroid immunogenes, antibody and detection reagent and preparation method
CN111830169B (en) * 2020-07-24 2022-07-12 中山大学 Compound for diagnosing polycystic ovarian syndrome and application thereof

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR672M (en) * 1960-08-31 1961-07-17
EP0424954A1 (en) * 1989-10-26 1991-05-02 Nippon Zoki Pharmaceutical Co. Ltd. Pharmaceutical composition for treatment of osteoporosis
US5206008A (en) * 1991-04-15 1993-04-27 Virginia Commonwealth University Enhancement of immune response
WO1993016704A1 (en) * 1992-02-24 1993-09-02 East Carolina University Method of inhibiting carcinogenesis by treatment with dehydroepiandrosterone and analogs thereof
WO1994016709A2 (en) * 1993-01-19 1994-08-04 Endorecherche Inc. Therapeutic uses and delivery systems of dehydroepiandrosterone
US5387583A (en) * 1993-04-20 1995-02-07 Loria; Roger M. Compositions containing corticosteroids or analogues thereof and corticosteroid buffering effective amounts of 5-androstene 3B, 17B or 5-androstene 3B, 7B, 17B triol or analogues thereof
US5461042A (en) * 1988-12-30 1995-10-24 Loria; Roger M. Regulation of the immune system
WO1997003676A1 (en) * 1995-07-21 1997-02-06 Cabo Soler Jose Novel pharmaceutical formulation of dehydroepiandrosterone for percutaneous topical application
WO1998056386A1 (en) * 1997-06-11 1998-12-17 Sunnimex Limited A medicament useful for the treatment of post-menopausal syndrome and osteoporosis, and for reducing fat mass and increasing lean body mass

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US424954A (en) * 1890-04-08 Table-knife
US279982A (en) * 1883-06-26 Thomas beid
US816689A (en) * 1904-07-07 1906-04-03 Charles M Stevenson Merry-go-round.
CH203260A (en) 1936-11-24 1939-02-28 Dreiding Boris Means for the local production of heat.
US2185187A (en) * 1938-05-23 1940-01-02 Vlieg Gerard A De Rotary cutter
US3797444A (en) 1971-04-19 1974-03-19 H Stubbs Towing guide
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US4139617A (en) * 1974-05-13 1979-02-13 Richardson-Merrell Inc. 19-Oxygenated-androst-5-enes for the enhancement of libido
US4040401A (en) 1974-11-05 1977-08-09 Ethyl Corporation Spark vacuum advance control
US4064654A (en) 1975-03-20 1977-12-27 H. G. Olson & Co., Inc. Sealed closures with weather stripping
JPS53144014A (en) 1977-05-20 1978-12-15 Masaya Koyama Automatic sprayer
DE3333240A1 (en) 1983-09-12 1985-03-28 Schering AG, 1000 Berlin und 4709 Bergkamen MEDIUM FOR TRANSDERMAL APPLICATION OF MEDICINAL PRODUCTS
US4634694A (en) 1984-01-14 1987-01-06 Akzo N.V. Novel Δ4 - and Δ5 -androstene derivatives and pharmaceutical compositions containing these derivatives
US4725439A (en) 1984-06-29 1988-02-16 Alza Corporation Transdermal drug delivery device
US4624665A (en) 1984-10-01 1986-11-25 Biotek, Inc. Method of transdermal drug delivery
US4568343A (en) 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
US5155045A (en) * 1985-01-25 1992-10-13 Trustees Of The University Of Penn. Use of male essence to alter female endocrine response
US4666441A (en) 1985-12-17 1987-05-19 Ciba-Geigy Corporation Multicompartmentalized transdermal patches
IE60941B1 (en) 1986-07-10 1994-09-07 Elan Transdermal Ltd Transdermal drug delivery device
US4816258A (en) 1987-02-26 1989-03-28 Alza Corporation Transdermal contraceptive formulations
US5887216A (en) * 1997-03-19 1999-03-23 Ricoh Company, Ltd. Method and system to diagnos a business office device based on operating parameters set by a user
US5686465A (en) * 1988-10-31 1997-11-11 Endorecherche Inc. Sex steroid activity inhibitors
CA2004203A1 (en) 1988-12-01 1990-06-01 Sharad K. Govil Compositions for transdermal delivery of estradiol
ATE170753T1 (en) * 1989-07-07 1998-09-15 Endorecherche Inc ANDROGEN DERIVATIVES FOR INHIBITING THE ACTIVITY OF SEXUAL STEROIDS
US5641768A (en) * 1989-11-17 1997-06-24 Loria; Roger M. 5-androstene 3β, 17β diol for treatment
US5071644A (en) 1990-08-07 1991-12-10 Mediventures, Inc. Topical drug delivery with thermo-irreversible gels
US5506223A (en) * 1990-08-29 1996-04-09 Humanetics Corporation Δ5-androstenes useful for promoting weight maintenance or weight loss and treatment process
US5183815A (en) * 1991-01-22 1993-02-02 Merck & Co., Inc. Bone acting agents
ZA924811B (en) * 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens
FR2696934B1 (en) * 1992-10-20 1995-06-02 Conservatoire Nal Arts Metiers Derivatives of natural hydroxyl 3B steroids having properties of triggering and stimulating immunity, composition containing them and process for obtaining them.
US5776923A (en) 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
US5571933A (en) * 1994-11-17 1996-11-05 Duquesne University Of The Holy Ghost Derivatives of estra 1,3,5(10)triene-17-one, 3-amino compounds and their use
US5828688A (en) * 1995-10-26 1998-10-27 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Method and apparatus for linewidth reduction in distributed feedback or distributed bragg reflector semiconductor lasers using vertical emission
US6653331B2 (en) * 1996-07-03 2003-11-25 Pharmacia & Upjohn Company Targeted drug delivery using sulfonamide derivatives
US5770226A (en) * 1996-07-10 1998-06-23 Wake Forest University Combined pharmaceutical estrogen-androgen-progestin oral contraceptive
US6139873A (en) * 1996-07-10 2000-10-31 Cedars-Sinai Medical Center Combined pharmaceutical estrogen-androgen-progestin
WO1999007381A1 (en) * 1997-08-11 1999-02-18 Weider Nutrition International, Inc. Compositions and treatments to reduce side effects of administration of androgenic testosterone precursors
CA2306837C (en) * 1997-10-28 2007-05-08 Asivi, Llc. Treatment of female sexual dysfunction
US5877216A (en) * 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction
EP1083904A2 (en) * 1998-06-11 2001-03-21 Endorecherche Inc. Pharmaceutical compositions and uses for androst-5-ene-3 beta,17 beta-diol
US6703381B1 (en) * 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
US6284262B1 (en) * 1999-01-26 2001-09-04 Virgil A. Place Compact dosage unit for buccal administration of a pharmacologically active agent
US6117446A (en) * 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents
CA2376158C (en) * 1999-07-06 2011-03-15 Endorecherche, Inc. Use of selective estrogen receptor modulators in the manufacture of medicaments for treating and/or suppressing weight gain
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20020107230A1 (en) * 2000-12-22 2002-08-08 Waldon R. Forrest Methods and formulations for the treatment of female sexual dysfunction
WO2002092102A2 (en) * 2001-05-16 2002-11-21 Endeavor Pharmaceuticals Treatment of conditions relating to hormone deficiencies by administration of progestins

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR672M (en) * 1960-08-31 1961-07-17
US5461042A (en) * 1988-12-30 1995-10-24 Loria; Roger M. Regulation of the immune system
EP0424954A1 (en) * 1989-10-26 1991-05-02 Nippon Zoki Pharmaceutical Co. Ltd. Pharmaceutical composition for treatment of osteoporosis
US5206008A (en) * 1991-04-15 1993-04-27 Virginia Commonwealth University Enhancement of immune response
WO1993016704A1 (en) * 1992-02-24 1993-09-02 East Carolina University Method of inhibiting carcinogenesis by treatment with dehydroepiandrosterone and analogs thereof
WO1994016709A2 (en) * 1993-01-19 1994-08-04 Endorecherche Inc. Therapeutic uses and delivery systems of dehydroepiandrosterone
US5387583A (en) * 1993-04-20 1995-02-07 Loria; Roger M. Compositions containing corticosteroids or analogues thereof and corticosteroid buffering effective amounts of 5-androstene 3B, 17B or 5-androstene 3B, 7B, 17B triol or analogues thereof
WO1997003676A1 (en) * 1995-07-21 1997-02-06 Cabo Soler Jose Novel pharmaceutical formulation of dehydroepiandrosterone for percutaneous topical application
WO1998056386A1 (en) * 1997-06-11 1998-12-17 Sunnimex Limited A medicament useful for the treatment of post-menopausal syndrome and osteoporosis, and for reducing fat mass and increasing lean body mass

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
ARANEO ET A.: "Dehydroepiandrosterone reduces progressive dermal ischemia caused by thermal injury", J. SURG. RES., vol. 59, no. 2, 1995, pages 250 - 262, XP002129031 *
BOCCUZZI G; DI MONACO M; BRIGNARDELLO E; LEONARDI L; GATTO V; PIZZINI A; GALLO M: "Dehydroepiandrosterone antiestrogenic action through androgen receptor in MCF-7 human breast-cancer cell line.", ANTICANCER RESEARCH, vol. 13, no. 6a, 1993, pages 2267 - 2272, XP000921483 *
C E BIRD ET AL: "Delta5-androstenediol: kinetics of metabolism and binding to plasma proteins in normal post-menopausal women", ACTA ENDOCRINOLOGICA,NO,SCANDINAVIAN UNIVERSITY PRESS, OSLO, vol. 99, no. 2, pages 309-313, XP002082225, ISSN: 0001-5598 *
COUILLARD, S.; LABRIE, C.; GAUTHIER, S.; LABRIE, F.: "Inhibitory effect of a new non-steroidal pure antiestrogen (EM-800) in combination with DHEA on human ZR-75-1 breast tumors in nude mice.", MATURITAS, vol. 27, no. suppl., 1997, pages 80, XP000922606 *
DAUVOIS S ET AL: "ANDROSTENEDIONE AND ANDROST-5-ENE-3BETA,17BETA-DIOL STIMULATE DMBA-INDUCED RAT MAMMARY TUMORS - ROLE OF AROMATASE", BREAST CANCER RESEARCH AND TREATMENT,US,NIJHOFF, BOSTON, vol. 13, no. 1, pages 61-69, XP000863496, ISSN: 0167-6806 *
DORGAN J F ET AL: "Relationship of serum dehydroepiandrosterone (DHEA), DHEA sulfate, and 5-androstene-3 beta, 17 beta-diol to risk of breast cancer in postmenopausal women.", CANCER EPIDEMIOLOGY, BIOMARKERS AND PREVENTION, (1997 MAR) 6 (3) 177-81., XP002129033 *
DOWSETT M.; CANTWELL B.; LAL A.; JEFFCOATE S.L.; HARRIS A.L.: "Suppression of postmenopausal ovarian steroidogenesis with the luteinizing hormone - releasing hormone agonist goserelin.", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, vol. 66, no. 4, 1988, pages 672 - 677, XP000923071 *
KUIPER ET AL.: "The Estrogen Receptor beta Subtype: A Novel Mediator of Estrogen Action in Neuroendocrine Systems", FRONTIERS IN NEUROENDOCRINOLOGY, vol. 19, no. 4, 1998, pages 253 - 286, XP002129032 *
LUO, S.; SOURLA, A.; LABRIE, C.; BELANGER, A.; LABRIE, F.: "Effects of combination of dehydroepiandrosterone and EM-800 on bone mass, serum lipids, and the development of dimethylbenz(A)anthracene (DMBA)-induced mammary carcinoma in the rat.", BREAST CANCER RESEARCH AND TREATMENT, vol. 46, no. 1, 1997, pages 55, XP000921456 *
LUO, SHOUQI; SOURLA, ANTIGONE; LABRIE, CLAUDE; BELANGER, ALAIN; LABRIE, FERNAND: "Combined effects of dehydroepiandrosterone and EM-800 on bone mass, serum lipids, and the development of dimethylbenz(A)anthracene-induced mammary carcinoma in the rat.", ENDOCRINOLOGY, vol. 138, no. 10, 1997, pages 4435 - 4444, XP000921482 *
MEYSKENS F L: "STRATEGY FOR CHEMOPREVENTION OF HUMAN BREAST CANCER.", CANCER INVEST., vol. 6, no. 5, 1988, pages 609 - 614, XP000923070 *
PASQUALINI J.R.: "Role of androgens in breast cancer.", JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, vol. 45, no. 1-3, - 1993, pages 167 - 172, XP000921485 *
TOURNIAIRE: "les limites de l'androgenotherapie", CAH. MED., vol. 15, no. 9, 1974, pages 583 - 588, XP002129030 *
YOSHIMOTO S ET AL: "Clinical effects of metharmon F for postmenopausal women with climacteric symptoms: its relationship with serum level of hormones.", HORUMON TO RINSHO. CLINICAL ENDOCRINOLOGY, (1983 AUG) 31 (8) 815-22., XP002129034 *

Also Published As

Publication number Publication date
CN1626095A (en) 2005-06-15
NO20006286D0 (en) 2000-12-11
EP1731157A2 (en) 2006-12-13
JP2002517432A (en) 2002-06-18
US20020187973A1 (en) 2002-12-12
EP1083904A2 (en) 2001-03-21
NO20006286L (en) 2001-01-31
TW200630101A (en) 2006-09-01
TWI283579B (en) 2007-07-11
US6995150B2 (en) 2006-02-07
ID27922A (en) 2001-05-03
TR200102867T2 (en) 2002-06-21
HUP0102483A3 (en) 2002-11-28
EP1731157A3 (en) 2009-07-15
NZ536787A (en) 2006-03-31
HK1078004A1 (en) 2006-03-03
KR100679735B1 (en) 2007-02-07
BR9911115A (en) 2001-12-04
US6964955B2 (en) 2005-11-15
US20020187970A1 (en) 2002-12-12
US6432940B1 (en) 2002-08-13
PL345955A1 (en) 2002-01-14
AU4127499A (en) 1999-12-30
KR20010052764A (en) 2001-06-25
CN1243550C (en) 2006-03-01
US20020187965A1 (en) 2002-12-12
WO1999063973A2 (en) 1999-12-16
CA2334702A1 (en) 1999-12-16
US20020187967A1 (en) 2002-12-12
IL175723A0 (en) 2006-09-05
US20020187962A1 (en) 2002-12-12
US20080161277A1 (en) 2008-07-03
CN1311682A (en) 2001-09-05
CA2334702C (en) 2005-10-18
AR018660A1 (en) 2001-11-28
KR20060098400A (en) 2006-09-18
US20020187968A1 (en) 2002-12-12
HUP0102483A2 (en) 2001-11-28
US20020187969A1 (en) 2002-12-12
ZA200007299B (en) 2002-04-24
RU2221569C2 (en) 2004-01-20
CN100377711C (en) 2008-04-02
TR200100063T2 (en) 2001-05-21
MY131522A (en) 2007-08-30
KR20060098399A (en) 2006-09-18
TWI263499B (en) 2006-10-11
IL140225A0 (en) 2002-02-10
US20020187963A1 (en) 2002-12-12
US20020187964A1 (en) 2002-12-12
US6884795B2 (en) 2005-04-26
MXPA00012304A (en) 2003-05-15
HK1037329A1 (en) 2002-02-08
US20020187966A1 (en) 2002-12-12
CN1879630A (en) 2006-12-20

Similar Documents

Publication Publication Date Title
WO1999063973A3 (en) PHARMACEUTICAL COMPOSITIONS AND USES FOR ANDROST-5-ENE-3β,17β-DIOL
Krattenmacher Drospirenone: pharmacology and pharmacokinetics of a unique progestogen
Sitruk-Ware Reprint of pharmacological profile of progestins
Sitruk-Ware New progestogens: a review of their effects in perimenopausal and postmenopausal women
RU2001101492A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING ANDROST-5-EH-3-β, 17β-DIOL, AND ITS USE
US6225298B1 (en) Compositions and methods for contraception and for treatment of benign gynecological disorders
DK1272504T3 (en) 8. Beta-hydrocarbyl-substituted estradiol for use as selective estrogens
Kloosterboer et al. Pros and cons of existing treatment modalities in osteoporosis: a comparison between tibolone, SERMs and estrogen (±progestogen) treatments
Foidart The contraceptive profile of a new oral contraceptive with antimineralocorticoid and antiandrogenic effects
JP2006525358A5 (en)
CN1156998A (en) Estra-1,3,5 (10)-triene derivatives, methods of preparing such compounds and pharmaceutical compositions containing them
HRP20030387A2 (en) Use of antiprogestins for prophylaxis and treatment of hormone dependent diseases
JP2006508951A5 (en)
JP2006507311A5 (en)
Messina et al. Antiandrogenic properties of spironolactone. Clinical trial in the management of female hirsutism
Wren et al. Differential clinical response to oestrogens after menopause
Bergink et al. Oestrogen binding proteins in the female genital trac
CN1270521A (en) Oral contraceptive preparation having a first phase comprising comprising progestin/estrogen and a second phase comprising progestin
AU781836B2 (en) Mesoprogestins (progesterone receptor modulators) as a component of compositions for hormone replacement therapy (HRT)
Palacios Tibolone: a tissue-specific approach to the menopause
US20010056087A1 (en) Use of 5alpha-androst-1en-3,17-diol to increase the level of the anabolic/androgenic hormone 17beta-hydroxy-5alpha-androst-1-en-3-one in humans
Rozenberg Clinical evidence supporting the rationale for constant oestrogen, intermittent progestogen hormone replacement therapy
Creatsas Possible Side-effects of Sexual Hormones
Oettel et al. What is past is prologue: estrogen/progestin replacement tomorrow
Husmann Clinical experiences with a combination of estradiol valerate and cyproterone acetate for hormone replacement

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99808637.1

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2334702

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020007014057

Country of ref document: KR

Ref document number: 41274/99

Country of ref document: AU

Ref document number: PA/a/2000/012304

Country of ref document: MX

Ref document number: 140225

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 508800

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1999924625

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2001/00063

Country of ref document: TR

WWP Wipo information: published in national office

Ref document number: 1999924625

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020007014057

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2001/02867

Country of ref document: TR

NENP Non-entry into the national phase

Ref country code: CA

WWG Wipo information: grant in national office

Ref document number: 1020007014057

Country of ref document: KR